Paul Tudor Jones’s Travere Therapeutics TVTX Stock Holding History

Paul Tudor Jones’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$329K	Buy	+5,800	New	+$257K	﹤0.01%	3066

Other funds holding TVTX

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Paul Tudor Jones's TVTX Position: Q2 2026 in Review

Paul Tudor Jones reduced its Travere Therapeutics (TVTX) stake by 82% in Q2 2026, selling an estimated $1.22M and leaving 5,955 shares worth $338K. The position accounts for ﹤0.01% of the portfolio, ranked #3052.

Paul Tudor Jones first reported a position in TVTX in Q2 2015 and has held it in 41 quarters since. The position peaked at $2.98M in Q2 2025. 317 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

Paul Tudor Jones held 5,955 shares of Travere Therapeutics worth $338K as of Q2 2026.
Paul Tudor Jones sold 27,406 Travere Therapeutics shares in Q2 2026, an estimated $1.22M.
Travere Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #3052 holding.
Paul Tudor Jones first reported a position in Travere Therapeutics in Q2 2015 and has held it in 41 quarters since.
Paul Tudor Jones's Travere Therapeutics position peaked at $2.98M in Q2 2025.
317 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.